<code id='D92D4DAE33'></code><style id='D92D4DAE33'></style>
      • <acronym id='D92D4DAE33'></acronym>
      <center id='D92D4DAE33'><center id='D92D4DAE33'><tfoot id='D92D4DAE33'></tfoot></center><abbr id='D92D4DAE33'><dir id='D92D4DAE33'><tfoot id='D92D4DAE33'></tfoot><noframes id='D92D4DAE33'>
      • <optgroup id='D92D4DAE33'><strike id='D92D4DAE33'><sup id='D92D4DAE33'></sup></strike><code id='D92D4DAE33'></code></optgroup>
        5. <b id='D92D4DAE33'><label id='D92D4DAE33'><select id='D92D4DAE33'><dt id='D92D4DAE33'><span id='D92D4DAE33'></span></dt></select></label></b><u id='D92D4DAE33'></u>
          <i id='D92D4DAE33'><strike id='D92D4DAE33'><tt id='D92D4DAE33'><pre id='D92D4DAE33'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-10-06 11:06:28 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：5453
                                  
                                    
          
                                   
          Darron Cummings/AP
          Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.
          The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.
          advertisement
          Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          JPM: CVS says Medicare Advantage patients are impacting profits
                                
                            
          Next article：  
                                      
                                          Walensky prepares to leave CDC — and Congress — behind
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles